Chris John Davis

Foresight Clearwater Fund, a joint venture between Clearwater Corporate Finance Ltd and Foresight Group LLP, invests in smaller companies located in the UK with revenues of £5 - £35 million and profitable. The fund targets companies operating across a wide variety of manufacturing and service sectors. It provides financing for buyouts and growth capital requirements with an investment size ranging up to £1 million in each transaction and requiring total investment size of less than £10 million.

MTI Partners Ltd (MTI Partners) is an independent venture capital firm founded in 1983. The firm is headquartered in UK.

MATRIX MicroScience was established in August 2000, with a market focus on the development of rapid microbiological tests for the food industry and more recently expanded into the environmental and bio-threat sectors. Current testing methods for the detection of micro-organisms in food are labor intensive and slow, typically taking up to 5 days to obtain a result. For many food types, such as fresh produce and beef, this is of little use. In response to market demand, MATRIX has developed a novel patented system called PATHATRIX. Using RIMS (re-circulating immuno-magnetic separation) technology, PATHATRIX can specifically purify and detect pathogens directly from complex food matrices within hours. For priority cases, the PATHATRIX can be coupled with rapid detection systems to produce a result in as little as 5 hours from point of sample. PATHATRIX employs proven technology at its core that can easily be adopted in any microbiology laboratory, with a minimum of training. Unlike other rapid methods, viable cultures are produced which enable full and detailed analysis of any positive result to be carried out without any further manipulation. PATHATRIX can be used to enhance the performance and reduce the number of 'false positives' of other rapid methods such as PCR, ELISA, chromomeric media etc., and by significantly reducing or eliminating the need for lengthy enrichment and/or selective enrichment steps. The highly innovative Pathatrix Pooling, AOAC-RI approved protocol, provides the customer with dramatic (5x) increase in sample throughput and very significant (>60%) reduction in analysis costs and labor. Sample integrity is maintained 100% enabling the rapid positive identification of individual samples. Linked to rapid methods it provides real-time microbiology for faster product release and incident investigation. Pathatrix has been successfully deployed in real life Salmonella and E.coli O157 outbreaks from contaminated food and has enables food companies and regulatory authorities to rapidly identify the source of contamination.

FSDC Plc engages in the provision of media and video content solutions. The company was founded by Jeffrey Steven Lenton and Michael John Brookes on March 16, 1999 and is headquartered in London, the United Kingdom.

Power Integrations UK Ltd. provides energy-efficient power conversion products. Its applications include mobile, feature, smart phones and media tablets. The company was founded by Gehan Anil Joseph Amaratunga and is headquartered in Cambridge the United Kingdom.

Nesta Investment Management LLP. (NESTA Investments) subsidiary of Nesta formerly NESTA, is a venture capital firm founded in 1998. The firm is headquartered in London city United Kingdom.

Inotec AMD Ltd. develops wound healing technologies. It provides solutions for chronic wounds, such as venous and pressure-induced leg ulcers and diabetic lesions. The company was founded by Melvin Frederick Vinton and Derek John Fray on December 23, 2003 and is headquartered in Cambridge, the United Kingdom.

AB-Polyblok Ltd. provides drug therapy for the treatment of alzheimer’s disease. It offers revolutionary technology which has the potential to treat and potentially partially reverse, the effects of Alzheimer ’s disease. The company is headquartered in Cambridge, the United Kingdom.

Thomas Swan Holdings Ltd. is a British chemical company founded in 1926 that produces over 100 performance and specialty chemicals. The private company is based in Consett, UK and is an expert in the manufacture of chemicals using state-of-the-art processing and solids isolation equipment. The company's products include a thickening agent for latex compounds, chemical peptisers for rubber, and catalyst and performance chemicals. The company also offers custom manufacturing services on a contract or toll basis.

NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018.